Cargando…
The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, a severe respiratory disease with varying clinical presentations and outcomes, and responsible for a major pandemic that started in early 2020. With no vaccines or effective antiviral treatments availabl...
Autores principales: | Müller, Christin, Obermann, Wiebke, Karl, Nadja, Wendel, Hans-Guido, Taroncher-Oldenburg, Gaspar, Pleschka, Stephan, Hartmann, Roland K., Grünweller, Arnold, Ziebuhr, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791309/ https://www.ncbi.nlm.nih.gov/pubmed/33422611 http://dx.doi.org/10.1016/j.antiviral.2021.105012 |
Ejemplares similares
-
Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates—A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics
por: Taroncher-Oldenburg, Gaspar, et al.
Publicado: (2021) -
Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (−) and the eIF4A-inhibitor Silvestrol
por: Müller, Christin, et al.
Publicado: (2020) -
Rocaglates as Antivirals: Comparing the Effects on Viral Resistance, Anti-Coronaviral Activity, RNA-Clamping on eIF4A and Immune Cell Toxicity
por: Obermann, Wiebke, et al.
Publicado: (2022) -
Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses
por: Müller, Christin, et al.
Publicado: (2018) -
Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates
por: Obermann, Wiebke, et al.
Publicado: (2023)